Analysts Anticipate vTv Therapeutics Inc (NASDAQ:VTVT) to Post -$0.11 Earnings Per Share

Equities analysts expect vTv Therapeutics Inc (NASDAQ:VTVT) to announce earnings per share (EPS) of ($0.11) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for vTv Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.06) and the lowest estimate coming in at ($0.16). vTv Therapeutics posted earnings per share of ($0.06) in the same quarter last year, which suggests a negative year over year growth rate of 83.3%. The firm is expected to issue its next earnings report on Thursday, November 14th.

According to Zacks, analysts expect that vTv Therapeutics will report full-year earnings of ($0.53) per share for the current fiscal year. For the next year, analysts expect that the business will report earnings of ($0.43) per share, with EPS estimates ranging from ($0.60) to ($0.25). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for vTv Therapeutics.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02. The company had revenue of $1.83 million during the quarter, compared to the consensus estimate of $1.63 million.

Several equities analysts have issued reports on the company. Northland Securities reiterated a “buy” rating and issued a $8.00 target price on shares of vTv Therapeutics in a research note on Thursday. ValuEngine upgraded vTv Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of vTv Therapeutics in a research note on Friday, August 16th. Finally, Zacks Investment Research upgraded vTv Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 19th.

In other vTv Therapeutics news, major shareholder Ronald O. Perelman purchased 150,000 shares of the company’s stock in a transaction dated Monday, August 19th. The shares were acquired at an average price of $1.31 per share, for a total transaction of $196,500.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Ronald O. Perelman purchased 606,061 shares of the company’s stock in a transaction dated Wednesday, September 18th. The shares were acquired at an average price of $1.65 per share, for a total transaction of $1,000,000.65. The disclosure for this purchase can be found here. Insiders acquired 3,550,787 shares of company stock worth $5,273,751 in the last quarter. 1.70% of the stock is owned by insiders.

An institutional investor recently bought a new position in vTv Therapeutics stock. Wedbush Securities Inc. purchased a new position in shares of vTv Therapeutics Inc (NASDAQ:VTVT) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 25,100 shares of the biotechnology company’s stock, valued at approximately $39,000. Hedge funds and other institutional investors own 1.64% of the company’s stock.

VTVT traded down $0.03 during trading on Tuesday, reaching $1.54. The company had a trading volume of 224,900 shares, compared to its average volume of 190,958. The business has a 50 day simple moving average of $1.48 and a 200-day simple moving average of $1.45. vTv Therapeutics has a 52 week low of $1.00 and a 52 week high of $3.50. The stock has a market cap of $84.99 million, a P/E ratio of -2.23 and a beta of -3.61.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.

Featured Story: What is the balance sheet?

Get a free copy of the Zacks research report on vTv Therapeutics (VTVT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.